MedTrace Logo

Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus

NCT02766049 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2016-07-20

No results posted yet for this study

Summary

The aim of this study was to assess tolerability and safety of three different formulations of an anti-HIV immunotherapy based on autologous dendritic cells (DCs) pulsed with HIV chemically inactivated with Aldrithiol™-2 (AT-2). Patients were chronically infected with HIV, naïve for antiretroviral drugs. A possible immunological and virological favorable impact was also assessed.

Conditions

  • HIV Infection

Interventions

BIOLOGICAL

DC

Autologous dendritic cells (3x10e7)

BIOLOGICAL

DC10e6+HIV-AT2

Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV

BIOLOGICAL

DC10e7+HIV-AT2

Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Alberto JS Duarte, Professor · University of Sao Paulo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-05-31
Completion
2014-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02766049 on ClinicalTrials.gov